CPN is pleased to be partnering with other patient and healthcare provider organizations globally on PsoProtect an international registry for health care providers to report outcomes of COVID-19 in individuals with psoriasis and psoriatic arthritis.

The immediate purpose of PsoProtect is to rapidly understand how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis. The PsoProtect website will provide real-time updates on cases reported for the benefit of the clinical community.

Dermatologists, rheumatologists and other healthcare providers can fill out a short form to report cases of COVID-19 in psoriasis patients. This form collects de-identified data and takes approximately 5 minutes to complete.
For more information, visit the PsoProtect FAQ page.

For patients:
PsoProtectMe is an online “self-report” survey for people with psoriasis. The purpose of the survey is to understand COVID-19 and how it affects people with psoriasis and whether the treatments we use for psoriasis increase (or decrease) the risk of severe infection. It is complementary to the PsoProtect registry that is filled out by health care providers. Anyone with psoriasis from any country in the world can take part, regardless of whether or not they have experienced COVID-19.